



**RECURRENT PERICARDITIS:
Because not all chest pain is an MI**

Visit the Kiniksa Booth #2641

at the American College of Cardiology's 68th Annual Scientific Session & Expo and learn more about recurrent pericarditis and the RHAPSODY study.



RHAPSODY

RILONACEPT INHIBITION OF IL-1 ALPHA AND BETA FOR RECURRENT PERICARDITIS: A PIVOTAL SYMPTOMATOLOGY AND OUTCOMES STUDY

**Visit the Kiniksa Booth #2641
to learn more about the
RHAPSODY study**

The RHAPSODY study is a phase 3, double-blind, placebo-controlled, randomized withdrawal study with open-label extension to assess the efficacy and safety of rilonacept in patients with recurrent pericarditis.

RhapsodyStudy.com

Rilonacept in recurrent pericarditis is an investigational drug.

© 2019 Kiniksa Pharmaceuticals, Ltd. All rights reserved. KUS-914-19036-01

